BioRestorative Therapies, Inc. 8-K

What Happened
BioRestorative Therapies, Inc. (BRTX) filed an 8-K on May 1, 2026 (Item 5.02) disclosing that its Compensation Committee approved discretionary cash bonuses for executive officers for the year ended December 31, 2025. The approved 2025 bonus amounts to be paid in 2026 are: CEO Lance Alstodt $300,000; VP of Research & Development Francisco Silva $287,500; and Chief Financial Officer Robert Kristal $140,000. The filing includes an updated Summary Compensation Table showing total 2025 compensation (including salary and grant‑date fair value of option awards) of $2,409,167 for Alstodt, $2,322,916 for Silva, and $801,750 for Kristal.

Key Details

• Filing date: May 1, 2026 (Form 8-K, Item 5.02).
• 2025 discretionary cash bonuses: Lance Alstodt (CEO) $300,000; Francisco Silva (VP R&D) $287,500; Robert Kristal (CFO) $140,000 — payable in 2026.
• Total 2025 compensation (per table): Alstodt $2,409,167; Silva $2,322,916; Kristal $801,750. Option awards (grant‑date fair value) drove much of the total: $1,512,500 (Alstodt), $1,468,750 (Silva), $318,000 (Kristal).
• 2024 discretionary bonuses are noted for context ($275,000, $262,500, $90,000) and were paid in 2025.

Why It Matters
This filing informs investors about management pay and upcoming cash outflows: the company approved discretionary cash bonuses for its top executives that will be paid in 2026. The compensation disclosure also highlights that a substantial portion of executive pay in 2025 was in the form of option awards (reported at grant‑date fair value), which is relevant for understanding executive incentives and potential future dilution. The 8-K does not report any departures or new appointments—this item solely covers compensation approvals.